NASDAQ:BNTX

SHAREHOLDER ALERT: Levi & Korsinsky Notifies BioNTech SE (BNTX) Investors of a Class Action Lawsuit and Upcoming Deadline

Retrieved on: 
Monday, February 5, 2024
Pfizer–BioNTech COVID-19 vaccine, COVID-19, COST, Telephone, BNTX, BioNTech, Risk, CLASS, LLP, Court, NEXT, Cryptocurrency

NEW YORK, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in BioNTech SE ("BioNTech" or the "Company") (NASDAQ: BNTX) of a class action securities lawsuit.

Key Points: 
  • NEW YORK, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in BioNTech SE ("BioNTech" or the "Company") (NASDAQ: BNTX) of a class action securities lawsuit.
  • CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of BioNTech investors who were adversely affected by alleged securities fraud between March 30, 2022 and October 13, 2023.
  • Follow the link below to get more information and be contacted by a member of our team:
    BNTX investors may also contact Joseph E. Levi, Esq.
  • For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

BNTX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that BioNTech SE Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Retrieved on: 
Monday, February 5, 2024
Pfizer–BioNTech COVID-19 vaccine, Pfizer, COVID-19, Omicron, BNTX, Biotechnology, BioNTech, Food, Risk, The Company, Complaint, Infection, Cancer, Court, Person, Pharmaceutical industry

BioNTech is a biotechnology company that develops and commercializes immunotherapies for cancer and other infectious diseases.

Key Points: 
  • BioNTech is a biotechnology company that develops and commercializes immunotherapies for cancer and other infectious diseases.
  • The Company has developed and continues to develop, among other products and product candidates, Comirnaty, a COVID-19 vaccine, in collaboration with Pfizer Inc. (“Pfizer”).
  • or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

Kessler Topaz Meltzer & Check, LLP: Important Deadline Reminder for BioNTech SE Investors in Securities Fraud Class Action Lawsuit

Retrieved on: 
Sunday, February 4, 2024
Pfizer–BioNTech COVID-19 vaccine, COVID-19, Lead, Ladewig, Annual report, ADS, Fraud, Omicron, News, BNTX, COPY, COVID, BioNTech, District court, IRS, CFTC, LLP, Court, Cost, Medicare, Person, Pharmaceutical industry

RADNOR, Pa. , Feb. 04, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Central District of California against BioNTech SE (“BioNTech”) ( NASDAQ: BNTX ).

Key Points: 
  • RADNOR, Pa. , Feb. 04, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Central District of California against BioNTech SE (“BioNTech”) ( NASDAQ: BNTX ).
  • The action charges BioNTech with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects.
  • As a result of BioNTech’ s materially misleading statements and omissions to the public, BioNTech’ s investors have suffered significant losses.
  • Kessler Topaz Meltzer & Check, LLP encourages BioNTech investors who have suffered significant losses to contact the firm directly to acquire more information.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioNTech SE of Class Action Lawsuit and Upcoming Deadlines – BNTX

Retrieved on: 
Saturday, February 3, 2024
Pfizer–BioNTech COVID-19 vaccine, Pfizer, Pomerantz, COVID-19, ADS, Ext, Research, Omicron, News, BNTX, COVID, Biotechnology, BioNTech, District court, Food, Action Replay, Third Bridge, Vaccination, Risk, Complaint, EUR, Infection, LLP, Court, Cancer, Cost, Person, Pharmaceutical industry

NEW YORK, Feb. 03, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against BioNTech SE (“BioNTech” or the “Company”) (NASDAQ: BNTX).

Key Points: 
  • NEW YORK, Feb. 03, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against BioNTech SE (“BioNTech” or the “Company”) (NASDAQ: BNTX).
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • BioNTech is a biotechnology company that develops and commercializes immunotherapies for cancer and other infectious diseases.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Mercury Systems, Onsemi, BioNTech, and BioVie and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, February 3, 2024
Pfizer–BioNTech COVID-19 vaccine, Mercury Systems, Onsemi, EPS, Silicon carbide, COVID-19, Pfizer, Growth, CFO, GAAP, OSI, GCP, Clinical trial, News, BNTX, Patient, Good clinical practice, Mercury, Tesla, Inc., P.C, Complaint, FDA, POC, EV, BioNTech, Food, LTSA, Silicon, Risk, Acquisition, MRCY, Defendant, Sale, Accreditation, Small business, Glass house, Pharmaceutical industry

Mercury Systems is a technology company that produces component modules and subsystems for the aerospace and defense industries.

Key Points: 
  • Mercury Systems is a technology company that produces component modules and subsystems for the aerospace and defense industries.
  • On this news, the price of Mercury Systems common stock fell more than 17%, the complaint alleges.
  • The Mercury Systems class action lawsuit alleges that on this news, the price of Mercury Systems common stock fell nearly 10%.
  • For more information on the BioVie class action go to: https://bespc.com/cases/BIVI

Maison Solutions, Dada Nexus, and BioNtech Class Action Update: Johnson Fistel Alerts Shareholders of Ongoing Legal Proceedings

Retrieved on: 
Friday, February 2, 2024
Pfizer–BioNTech COVID-19 vaccine, COVID-19, SAN, Register, Supermarket, Marketing, BioNTech, Risk, Learning, EB-5, LLP, Complaint, Sales

SAN DIEGO, Feb. 02, 2024 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP, a law firm specializing in shareholder rights, has announced the initiation of class action lawsuits on behalf of investors of the following companies.

Key Points: 
  • SAN DIEGO, Feb. 02, 2024 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP, a law firm specializing in shareholder rights, has announced the initiation of class action lawsuits on behalf of investors of the following companies.
  • Investors are encouraged to review the deadlines listed and submit their information.
  • If you suffered a loss and are interested in learning more about being a lead plaintiff, please contact Jim Baker ([email protected]) by email or phone at 619-814-4471.
  • If you suffered a loss and are interested in learning more about being a lead plaintiff, please contact Jim Baker ([email protected]) by email or phone at 619-814-4471.

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Counsel Before Important Deadline in Securities Class Action – BNTX

Retrieved on: 
Friday, February 2, 2024
Titan, Pfizer–BioNTech COVID-19 vaccine, Pfizer, COVID-19, Class, Advertising, BNTX, BioNTech, Risk, Court

WHAT TO DO NEXT: To join the BioNTech class action, go to https://rosenlegal.com/submit-form/?case_id=21850 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the BioNTech class action, go to https://rosenlegal.com/submit-form/?case_id=21850 or call Phillip Kim, Esq.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

BIONTECH INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In BioNTech To Contact Him Directly To Discuss Their Options

Retrieved on: 
Friday, February 2, 2024
Pfizer–BioNTech COVID-19 vaccine, COVID-19, ADS, Research, Advertising, Omicron, News, BNTX, COVID, BioNTech, Food, Third Bridge, Vaccination, Risk, The Company, EUR, Woman, LLP, Court, Cost, Pharmaceutical industry

NEW YORK, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against BioNTech SE (“BioNTech” or the “Company”) (NASDAQ: BNTX) and reminds investors of the March 12, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Key Points: 
  • Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • The Company attributed the result, in part, to the "dynamic" development of the pandemic, which "caus[ed] a re-phasing of orders and .
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding BioNTech’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
  • The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com ).

DEADLINE ALERT for DADA, BNTX, and CMI: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

Retrieved on: 
Friday, February 2, 2024
Nexus, Pfizer–BioNTech COVID-19 vaccine, COVID-19, Pfizer, Marketing, Investment, BioNTech, Law, Risk, The Company, Defendant, Suite, Security (finance)

LOS ANGELES, Feb. 02, 2024 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.

Key Points: 
  • LOS ANGELES, Feb. 02, 2024 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.
  • Investors have until the deadlines listed below to file a lead plaintiff motion.
  • Investors suffering losses on their investments are encouraged to contact The Law Offices of Frank R. Cruz to discuss their legal rights in these class actions at 310-914-5007 or by email to [email protected] .
  • The Law Offices of Frank R. Cruz, Los Angeles

SHAREHOLDER ALERT: Levi & Korsinsky Notifies BioNTech SE (BNTX) Investors of a Class Action Lawsuit and Upcoming Deadline

Retrieved on: 
Thursday, February 1, 2024
Pfizer–BioNTech COVID-19 vaccine, COVID-19, COST, Telephone, BNTX, BioNTech, Risk, CLASS, LLP, Court, NEXT, Cryptocurrency

NEW YORK, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in BioNTech SE ("BioNTech" or the "Company") (NASDAQ: BNTX) of a class action securities lawsuit.

Key Points: 
  • NEW YORK, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in BioNTech SE ("BioNTech" or the "Company") (NASDAQ: BNTX) of a class action securities lawsuit.
  • CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of BioNTech investors who were adversely affected by alleged securities fraud between March 30, 2022 and October 13, 2023.
  • Follow the link below to get more information and be contacted by a member of our team:
    BNTX investors may also contact Joseph E. Levi, Esq.
  • For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.